Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine's Anti-suicidal Ideation Effect in MDD
NCT07139106Phase 4Not yet recruiting
- Sponsor
- New York State Psychiatric Institute
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ketamine in major depressive disorder (MDD), sponsored by New York State Psychiatric Institute. Primary endpoint: Scale for Suicidal Ideation at 24 hours. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07139106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07139106.